利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

42 条记录 (耗时 0.033 秒)

    RNA-CODED ANTIBODY
    1.
    发明申请
    RNA-CODED ANTIBODY 有权

    公开(公告)号：US20220372158A1

    公开(公告)日：2022-11-24

    申请号：US17813530

    申请日：2022-07-19

    申请人： CureVac AG

    发明人： Ingmar HOERR ,  Jochen PROBST ,  Steve PASCOLO

    IPC分类号： C07K16/28 ,  C07K16/32

    摘要： The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.

    RNA-CODED ANTIBODY
    2.
    发明申请
    RNA-CODED ANTIBODY 审中-公开

    公开(公告)号：US20190284260A1

    公开(公告)日：2019-09-19

    申请号：US16392004

    申请日：2019-04-23

    申请人： CureVac AG

    发明人： Ingmar HOERR ,  Jochen PROBST ,  Steve PASCOLO

    IPC分类号： C07K16/10 ,  C07K16/28 ,  A61K48/00 ,  C07K16/32 ,  A61K39/42 ,  C07K16/30 ,  A61K39/395 ,  A61K39/40 ,  A61K9/00

    摘要： The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.

    COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC)
    3.
    发明申请
    COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) 审中-公开

    公开(公告)号：US20160346370A1

    公开(公告)日：2016-12-01

    申请号：US15145746

    申请日：2016-05-03

    申请人： CureVac AG

    发明人： Marijke BARNER ,  Jochen PROBST ,  Thomas LANDER ,  Ingmar HOERR

    IPC分类号： A61K39/00

    CPC分类号： A61K39/0011 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70

    摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

    COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC)
    4.
    发明申请
    COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) 审中-公开

    公开(公告)号：US20160317636A1

    公开(公告)日：2016-11-03

    申请号：US15145540

    申请日：2016-05-03

    申请人： CureVac AG

    发明人： Marijke BARNER ,  Jochen PROBST ,  Thomas LANDER ,  Ingmar HOERR

    IPC分类号： A61K39/00

    CPC分类号： A61K39/0011 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70

    摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

    NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN
    7.
    发明申请
    NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN 有权

    公开(公告)号：US20210393755A1

    公开(公告)日：2021-12-23

    申请号：US17393253

    申请日：2021-08-03

    申请人： CureVac AG

    发明人： Andreas THESS ,  Thomas SCHLAKE ,  Jochen PROBST

    IPC分类号： A61K39/00 ,  C07K14/47 ,  C12N15/67 ,  C12N15/63

    摘要： The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of cancer or tumour diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

    NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT
    8.
    发明申请
    NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT 审中-公开

    公开(公告)号：US20200085942A1

    公开(公告)日：2020-03-19

    申请号：US16541376

    申请日：2019-08-15

    申请人： CureVac AG

    发明人： Thomas KRAMPS ,  Söhnke VOSS ,  Jochen PROBST ,  Ingmar HOERR

    IPC分类号： A61K39/39 ,  C12N15/117 ,  C07H21/00

    摘要： The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

    COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY
    10.
    发明申请
    COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY 审中-公开
    PD-1途径的接种和抑制的组合

    公开(公告)号：US20160206719A1

    公开(公告)日：2016-07-21

    申请号：US15091060

    申请日：2016-04-05

    申请人： CureVac AG

    发明人： Mariola FOTIN-MLECZEK ,  Karl-Josef KALLEN ,  Jochen PROBST

    IPC分类号： A61K39/00 ,  A61K39/395

    CPC分类号： A61K39/0011 ,  A61K39/0005 ,  A61K39/39 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/55516 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/76 ,  Y02A50/491 ,  A61K2300/00

    摘要： The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.

    摘要翻译： 本发明涉及疫苗/抑制剂组合物，其包含RNA疫苗，其包含至少一种RNA，其包含至少一种编码至少一种抗原的开放阅读框（ORF）和包含至少一种PD-1途径抑制剂的组合物，优选导向 针对PD-1受体或其配体PD-L1和PD-L2。 本发明还涉及包含这种疫苗/抑制剂组合的组分的药物组合物和试剂盒。 另外，本发明涉及这种疫苗/抑制剂组合的医学用途，药物组合物和包含这种疫苗/抑制剂组合的部分试剂盒，特别是用于预防或治疗肿瘤或癌症疾病或感染性疾病。 此外，本发明涉及RNA疫苗在与PD-1途径抑制剂联合治疗中的用途以及PD-1途径抑制剂在与RNA疫苗联合治疗中的应用。